Efficacy and Safety Study of Soluble Beta-1,3/1,6-Glucan in Thermal Burns
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00283426|
Recruitment Status : Terminated (Slow patient recruitment)
First Posted : January 30, 2006
Last Update Posted : March 19, 2007
The purpose of this study is to determine whether soluble beta-1,3/1,6-glucan is an effective and safe treatment of thermal burns and non-injured skin where skin grafts are harvested.
Hypothesis: Soluble beta-1,3/1,6-glucan will through its immunomodulating activities improve wound healing of thermal burns and non-injured skin where skin grafts are harvested.
|Condition or disease||Intervention/treatment||Phase|
|Burns||Drug: Soluble beta-1,3/1,6-glucan||Phase 1|
In severe cases, burn patients commonly exhibit a clinical picture of systemic inflammation with a variety of manifestations ranging from the presence of tachycardia, tachypnea, fever and leukocytosis, and may progress to refractory hypotension. Shock and multiple organ system dysfunction may subsequently occur. Sepsis, caused by infection or bacteremia, is also a common occurrence and a major complication in burn patients.
After cooling the burned area, pain control is important. Local burn wound care starts with cleansing the wound followed by application of topical agents to prevent infection. Such agents may have adverse local or systemic effects and may impede on the wound healing process itself. The use of synthetic or biologic materials for wound covering is becoming increasingly popular, but most of the clinical information about efficacy of such products are anecdotal.
A primary objective in burn care is to have all wounds healed within 1 month. With longer healing periods, there is an increasing likelihood of developing hypertropic scaring and alterations in pigmentation. The development of an effective wound healing agent would therefore be highly beneficial for the suffering patient in terms of decreased healing time and improved cosmetic results.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open Clinical Feasibility Study to Evaluate Efficacy and Safety of Soluble Beta-1,3/1,6-Glucan in Thermal Burns|
|Study Start Date :||January 2006|
|Study Completion Date :||March 2007|
- Efficacy parameters:
- pain on physical contact
- capillary refill
- infectious discharge
- adherence of dressing
- time since last dressing change
- The efficacy parameters will be recorded during regular wound procedures
- Safety parameters:
- vital signs (heart rate, blood pressure, body temperature)
- adverse events
- laboratory parameters
- The safety parameters will be recorded daily during the first week of treatment and weekly thereafter
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00283426
|Haukeland University Hospital|
|Bergen, Norway, 5021|
|Principal Investigator:||Tjostolv Lund, Dr.med.||Haukeland University Hospital|